| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Medicine, Divisions of Medical Oncology and Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
Correspondence: Wooin Lee, Ph.D., 542 RRB, 23rd Avenue at Pierce Avenue, Division of Hematology and Oncology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-6602, USA. Telephone: 615-343-3512; Fax: 615-322-4707; e-mail: wooin.lee{at}vanderbilt.edu
Interindividual differences in tumor response and normal tissue toxicities are consistently observed with most chemotherapeutic agents or regimens. While many clinical variables have been associated with drug responses (e.g., age, gender, diet, drug-drug interactions), inherited variations in drug disposition (metabolism and transport) genes and drug target genes also likely contribute to the observed variability in cancer treatment outcome. Pharmacogenomic studies aim to elucidate the genetic bases for interindividual differences and to use such genetic information to predict the safety, toxicity, and/or efficacy of drugs. There exist several clinically relevant examples of the utility of pharmacogenomics that associate specific genetic polymorphisms in drug metabolizing enzymes (e.g., TPMT, UGT1A1, DPD), drug transporters (MDR1), and drug target enzymes (TS) with clinical outcomes in patients treated with commonly prescribed chemotherapy drugs, such as 5-fluorouracil and irinotecan (Camptosar®; Pfizer Pharmaceuticals; New York, NY http://www.pfizer.com). Techniques to discover and evaluate the functional significance of these polymorphisms have evolved in recent years and may soon be applied to clinical practice and clinical trials of currently prescribed anticancer drugs as well as new therapeutic agents. This review discusses the current and future applications of pharmacogenomics in clinical cancer therapy and cancer drug development.
This article has been cited by other articles:
 |
|
 |
|
  M. J. Duffy and J. Crown A Personalized Approach to Cancer Treatment: How Biomarkers Can Help Clin. Chem., November 1, 2008; 54(11): 1770 - 1779. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Li, O. Mezei, and N. F. Shay Human and Murine Hepatic Sterol-12-{alpha}-Hydroxylase and Other Xenobiotic Metabolism mRNA Are Upregulated by Soy Isoflavones J. Nutr., July 1, 2007; 137(7): 1705 - 1712. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Milani, M. Gupta, M. Andersen, S. Dhar, M. Fryknas, A. Isaksson, R. Larsson, and A.-C. Syvanen Allelic imbalance in gene expression as a guide to cis-acting regulatory single nucleotide polymorphisms in cancer cells Nucleic Acids Res., March 12, 2007; 35(5): e34 - e34. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Matsukuma, M. Yoshihara, F. Kasai, A. Kato, A. Yoshida, M. Akaike, O. Kobayashi, H. Nakayama, Y. Sakuma, T. Yoshida, et al. Rapid and Simple Detection of Hot Spot Point Mutations of Epidermal Growth Factor Receptor, BRAF, and NRAS in Cancers Using the Loop-Hybrid Mobility Shift Assay J. Mol. Diagn., September 1, 2006; 8(4): 504 - 512. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Reed, R. M. Califf, and K. A. Schulman How Changes In Drug-Safety Regulations Affect The Way Drug And Biotech Companies Invest In Innovation Health Aff., September 1, 2006; 25(5): 1309 - 1317. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. H. Ezzeldin and R. B. Diasio Genetic testing in cancer therapeutics. Clin. Cancer Res., July 15, 2006; 12(14): 4137 - 4141. [Full Text] [PDF]
|
|
|
|
 |
|
 D. C. Drummond, C. O. Noble, Z. Guo, K. Hong, J. W. Park, and D. B. Kirpotin Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res., March 15, 2006; 66(6): 3271 - 3277. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| THE ONCOLOGIST | STEM CELLS | CME | ALPHAMED PRESS JOURNALS |
